Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ring finger protein 214 (RNF214) is a member of the RING finger ubiquitin ligase family, a group of enzymes that label substrate proteins with ubiquitin, thereby influencing their function, interactions, or localization[1][2][4][5]. RNF214 induces non-proteolytic ubiquitylation of TEAD transcription factors, thereby enhancing their interaction with YAP/TAZ and increasing the expression of Hippo pathway target genes[1]. RNF214 is involved in cell proliferation and is notably overexpressed in hepatocellular carcinoma, where it is associated with poor differentiation and reduced patient survival, acting as a potential oncogene and candidate therapeutic target in this cancer type. Its broader physiological and pathological roles remain understudied, but available evidence implicates RNF214 in general processes of transcriptional regulation, cancer biology, and possibly in other tumor types[1][6].
Ubiquitin ligase activity targeting TEAD transcription factors (modulating Hippo pathway output)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ring finger protein 214 (RNF214).